VEGFA and Parkinson disease: In the human disease, our analysis of the national insurance database of more than 200,000 patients treated by anti-VEGF IVT confirms that patients with PD and treated with l-DOPA/DDI were significantly older at the beginning of treatment for nAMD and required fewer anti-VEGF injections than other patients.